

Current Clinical Controversies and Promising Therapeutic Strategies in Advanced Prostate Cancer

A Live Clinical Investigator Think Tank

CME INFORMATION

TARGET AUDIENCE

This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals.

OVERVIEW OF ACTIVITY

Cancer of the genitourinary system affects hundreds of thousands of individuals within the United States each year and accounts for almost 30% of all newly diagnosed tumors in humans. Tumors of the prostate are among the most prevalent and thus a topic of extensive ongoing clinical research. Consequently, the management of prostate cancer is continuously in a state of evolution, necessitating rapid and consistent access to learning opportunities for medical oncologists, radiation oncologists, urologists and other healthcare providers who treat the disease. These proceedings from an interactive CME symposium held during the 2013 Genitourinary Cancers Symposium offer medical professionals a multifaceted educational experience focused specifically on the current treatment of prostate cancer.

LEARNING OBJECTIVES

- Review the known efficacy and safety data related to radium-223 chloride in patients with skeletal metastases in preparation for its potential approval.
- Recall existing and emerging research information demonstrating the impact of secondary hormonal interventions on quality and quantity of life for patients with chemotherapy-naïve or pretreated castration-resistant prostate cancer, and use this information to guide treatment planning for these patients.
- Recognize the unique patterns of response with available and emerging immunotherapeutic strategies, and effectively counsel patients considering these treatments.
- Effectively apply evidence-based research findings in the determination of best-practice sequencing of available immunotherapeutics, chemotherapeutics and secondary hormonal agents for patients with metastatic prostate cancer.
- Explore the emerging data and active research evaluating novel agents in the setting of advanced prostate cancer in

order to prioritize clinical trial opportunities for appropriate patients.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 2.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/GUCancers13/ThinkTank/CME.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Daniel J George, MD

Associate Professor of Medicine and Surgery
Director of Genitourinary Oncology Program
Duke Cancer Institute
Durham, North Carolina

Advisory Committee: Aveo Pharmaceuticals, Dendreon Corporation, Medivation Inc, Pfizer Inc, Sanofi, Viamet Pharmaceuticals Inc; **Consulting Agreements:** Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Dendreon Corporation, Exelixis Inc, Genentech BioOncology, Medivation Inc, Molecular Insight, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sanofi, Teva Oncology; **Contracted Research:** Exelixis Inc, Genentech BioOncology, GlaxoSmithKline, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc; **Speakers Bureau:** Dendreon Corporation, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi.

Robert Dreicer, MD, MS

Chairman, Department of Solid Tumor Oncology
Taussig Cancer Institute
Cleveland Clinic
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Cleveland, Ohio

Advisory Committee: EMD Serono Inc, Janssen Pharmaceuticals Inc, Lilly USA LLC, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation.

A Oliver Sartor, MD

Medical Director, Tulane Cancer Center
Laborde Professor of Cancer Research
Professor of Medicine and Urology
Tulane Medical School
New Orleans, Louisiana

Advisory Committee: Bayer HealthCare Pharmaceuticals, Sanofi; **Consulting Agreements:** Algeta ASA, Bayer HealthCare Pharmaceuticals, Celgene Corporation, GlaxoSmithKline, Medivation Inc, Millennium: The Takeda Oncology Company, OncoGenex Pharmaceuticals Inc, Pfizer Inc, Sanofi; **Contracted Research:** AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Millennium: The Takeda Oncology Company, Sanofi.

Celestia S Higano, MD

Professor of Medicine and Urology
University of Washington School of Medicine
Member, Fred Hutchinson Cancer Research Center
Seattle Cancer Care Alliance
Seattle, Washington

Advisory Committee: Amgen Inc, Aragon Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Dendreon Corporation, Endo Pharmaceuticals, Exelixis Inc, Medivation Inc, Millennium: The Takeda Oncology Company, National Cancer Institute, Novartis Pharmaceuticals Corporation, OncoGenex Pharmaceuticals Inc, Teva Oncology, US Department of Defense, Veridex LLC; **Consulting Agreements:** Amgen Inc, Aragon Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Dendreon Corporation, Exelixis Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Medivation Inc, Millennium: The Takeda Oncology Company, National Cancer Institute, Novartis Pharmaceuticals Corporation, OncoGenex Pharmaceuticals Inc, Teva Oncology, US Department of Defense; **Contracted Research:** Aragon Pharmaceuticals,

Dendreon Corporation, Exelixis Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Medivation Inc, Millennium: The Takeda Oncology Company, National Cancer Institute, OncoGenex Pharmaceuticals Inc, Teva Oncology, US Department of Defense.

Christopher J Logothetis, MD

Chairman/Professor, Genitourinary Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Paid Research: Dendreon Corporation, Johnson & Johnson Pharmaceuticals.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

RESEARCH TO PRACTICE STAFF AND EXTERNAL

REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Algeta US/Bayer HealthCare Pharmaceuticals, Astellas/Medivation Inc, Dendreon Corporation, Millennium: The Takeda Oncology Company and Teva Oncology.

Hardware/Software Requirements:

A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: May 2013

Expiration date: May 2014

George

Attard G et al. **Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.** *J Clin Oncol* 2008;26(28):4563-71.

De Bono JS et al. **Abiraterone and increased survival in metastatic prostate cancer.** *N Engl J Med* 2011;364(21):1995-2005.

Fizazi K et al. **Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.** *Lancet Oncol* 2012;13(10):983-92.

Montgomery BR et al. **Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth.** *Cancer Res* 2008;68(11):4447-54.

Payne AH, Hales DB. **Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones.** *Endocr Rev* 2004;25(6):947-70.

Ryan CJ et al. **Abiraterone in metastatic prostate cancer without previous chemotherapy.** *N Engl J Med* 2013;368(2):138-48.

Van der Goes MC et al. **Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice.** *Ann Rheum Dis* 2010;69(11):1913-9.

Dreicer

Clegg NJ et al. **ARN-509: A novel antiandrogen for prostate cancer treatment.** *Cancer Res* 2012;72(6):1494-503.

Efstathiou E et al. **MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: A preliminary report.** Genitourinary Cancers Symposium 2011;Abstract 4501.

Scher HI et al. **Antitumor activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study.** *Lancet* 2010;375(9724):1437-46.

Sartor

Bruland ØS et al. **High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: Adjuvant or alternative to conventional modalities?** *Clin Cancer Res* 2006;12(20 Pt 2):6250s-7s.

Henriksen G et al. **Targeting of osseous sites with alpha-emitting 223Ra: Comparison with the beta-emitter 89Sr in mice.** *J Nucl Med* 2003;44(2):252-9.

McDevitt MR et al. **Radioimmunotherapy with alpha-emitting nuclides.** *Eur J Nucl Med* 1998;25(9):1341-51.

Parker C et al. **Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).** *Proc ASCO* 2012;Abstract LBA4512.

Higano

Drake CG et al. **Prostate cancer as a model for tumour immunotherapy.** *Nat Rev Immunol* 2010;10(8):580-93.

Higano CS et al. **Predictors of outcome and subgroup results from the integrated analysis of sipuleucel-T trials in metastatic castration-resistant prostate cancer.** *Proc ASCO* 2010;Abstract 4550.

Kantoff PW et al. **Sipuleucel-T immunotherapy for castration-resistant prostate cancer.** *N Engl J Med* 2010;363(5):411-22.

Madan RA et al. **Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: A phase 1 dose-escalation trial.** *Lancet Oncol* 2012;13(5):501-8.

Small EJ et al. **Time to disease-related pain after sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): Results from three randomized phase III trials.** *Proc ASCO* 2011;Abstract 4661.

Logothetis

Chi KN et al. **A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.** *J Natl Cancer Inst* 2005;97(17):1287-96.

Corn PG. **The tumor microenvironment in prostate cancer: Elucidating molecular pathways for therapy development.** *Cancer Manag and Res* 2012;4:183-93.

Park SI et al. **Targeting Src family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model.** *Cancer Res* 2008;68(9):3323-33.

Tzelepi V et al. **Modulation of candidate therapy targets in regionally advanced prostate cancer by androgen ablation and docetaxel.** *Proc ASCO* 2010;Abstract 4663.